ARGX Stock Up 19% after 9-Day Win Streak
argenx (ARGX) stock hit day 9 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 19% return. The company has gained about $7.7 Bil in value over the last 9 days, with its current market capitalization at about $41 Bil. The stock remains 9.0% above its value at the end of 2024. This compares with year-to-date returns of 7.8% for the S&P 500.
ARGX biotechnology company developing therapies for autoimmune diseases, including efgartigimod for multiple conditions, and immunology innovations like cusatuzumab for hematological cancers and high-risk MDS.
Comparing ARGX Stock Returns With The S&P 500
The following table summarizes the return for ARGX stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | ARGX | S&P 500 |
|---|---|---|
| 1D | 11.9% | -0.4% |
| 9D (Current Streak) | 18.7% | 0.7% |
| 1M (21D) | 23.6% | 2.3% |
| 3M (63D) | 3.9% | 13.8% |
| YTD 2025 | 9.0% | 7.8% |
| 2024 | 61.7% | 23.3% |
| 2023 | 0.4% | 24.2% |
| 2022 | 8.2% | -19.4% |
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades. However, big gains can follow sharp reversals – but how has ARGX behaved after prior drops? See ARGX Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 35 S&P constituents with 3 days or more of consecutive gains and 127 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 23 | 40 |
| 4D | 6 | 60 |
| 5D | 1 | 10 |
| 6D | 1 | 15 |
| 7D or more | 4 | 2 |
| Total >=3 D | 35 | 127 |
Key Financials for argenx (ARGX)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $1.2 Bil | $2.2 Bil |
| Operating Income | $-420.6 Mil | $-17.8 Mil |
| Net Income | $-295.1 Mil | $833.0 Mil |
Last 2 Fiscal Quarters:
| Metric | 2024 FQ4 | 2025 FQ1 |
|---|---|---|
| Revenues | $738.4 Mil | $790.7 Mil |
| Operating Income | $101.6 Mil | $141.2 Mil |
| Net Income | $774.2 Mil | $169.5 Mil |
While ARGX stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.